![]() ![]() ![]() A relevant relationship allying clinical characteristics and plasma drug levels and/or pharmacodynamics responses with safety and efficacy has been established by pharmacokinetics-pharmacodynamics analyses of vital trials with NOACs. Due to this appreciable characteristic, NOACs are used at fixed doses without periodic monitoring of coagulation parameters. Unlike VKAs, NOACs have more predictable PK-PD properties. It equips an overview of NOAC and deals with the following areas: (i) pharmacology, (ii) laboratory methods, (iii) peri-operative management, (iv) advantages, (v) challenges, and (vi) future. This article aims to provide quick and brief information on the novel class of drugs. Therefore, a basic understanding on these drugs is highly recommended to provide a better service to the patients. ![]() The upcoming years are known to be NOACs’ age due to the significant findings in this area. Also, the studies have shown that NOACs have lesser bleeding complications and associated mortality in contrast to traditional anticoagulants. The recent surveys reveal that use of NOACs has steeply increased due to its safety profile and convenience to use. Rivaroxaban and apixaban are approved for prophylaxis of thrombus following surgical hip or knee arthroplasty. The drugs are licenced to prevent stroke and also systemic embolism in patients on treatment for atrial fibrillation and prevent venous thromboembolism. These agents are dabigatran, rivaroxaban, apixaban, and edoxaban. It has displaced vitamin K antagonists, notably warfarin, for many indications. NOACs, commonly known as novel oral anticoagulants, are the non-vitamin K antagonist oral anticoagulants which are relatively newer in the market.
0 Comments
Leave a Reply. |